Electromed (ELMD) Competitors

Electromed has a net margin of 11.34% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 30.75% beat Electromed's return on equity.

40.8% of Electromed shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Electromed presently has a consensus price target of $36.67, indicating a potential upside of 36.51%. Bioventus has a consensus price target of $14.00, indicating a potential upside of 31.46%. Given Electromed's higher possible upside, analysts clearly believe Electromed is more favorable than Bioventus.

In the previous week, Bioventus had 11 more articles in the media than Electromed. MarketBeat recorded 11 mentions for Bioventus and 0 mentions for Electromed. Electromed's average media sentiment score of 0.67 beat Bioventus' score of 0.63 indicating that Electromed is being referred to more favorably in the media.

Electromed has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Bioventus has higher revenue and earnings than Electromed. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Electromed has a net margin of 11.34% compared to CeriBell's net margin of -59.97%. Electromed's return on equity of 15.71% beat CeriBell's return on equity.

40.8% of Electromed shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Electromed presently has a consensus price target of $36.67, indicating a potential upside of 36.51%. CeriBell has a consensus price target of $23.20, indicating a potential upside of 13.84%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than CeriBell.

In the previous week, CeriBell had 6 more articles in the media than Electromed. MarketBeat recorded 6 mentions for CeriBell and 0 mentions for Electromed. Electromed's average media sentiment score of 0.67 beat CeriBell's score of 0.63 indicating that Electromed is being referred to more favorably in the media.

Electromed has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, CeriBell has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Electromed has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Electromed has a net margin of 11.34% compared to Spyglass Pharma's net margin of 0.00%. Electromed's return on equity of 15.71% beat Spyglass Pharma's return on equity.

In the previous week, Electromed's average media sentiment score of 0.67 beat Spyglass Pharma's score of 0.00 indicating that Electromed is being referred to more favorably in the media.

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Electromed presently has a consensus price target of $36.67, indicating a potential upside of 36.51%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 77.24%. Given Spyglass Pharma's higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than Electromed.

Electromed has higher revenue and earnings than Spyglass Pharma.

Electromed has a net margin of 11.34% compared to Alpha Tau Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Alpha Tau Medical's return on equity.

Electromed has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

In the previous week, Alpha Tau Medical had 10 more articles in the media than Electromed. MarketBeat recorded 10 mentions for Alpha Tau Medical and 0 mentions for Electromed. Electromed's average media sentiment score of 0.67 beat Alpha Tau Medical's score of 0.10 indicating that Electromed is being referred to more favorably in the media.

40.8% of Electromed shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Electromed presently has a consensus price target of $36.67, indicating a potential upside of 36.51%. Alpha Tau Medical has a consensus price target of $8.67, indicating a potential upside of 10.40%. Given Electromed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Electromed is more favorable than Alpha Tau Medical.

Electromed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.